Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-08-25
1996-04-02
Robinson, Allen J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549384, A61K 3135, C07D31178
Patent
active
055041035
ABSTRACT:
17.beta.-hydroxywortmannin and certain of its analogs are inhibitors of phosphatidylinositol 3-kinase. The compounds are particularly useful for inhibiting phosphatidylinositol 3-kinase in mammals and for treating phosphatidylinositol 3-kinase-dependent conditions, especially neoplasms, in mammals.
REFERENCES:
patent: 3668222 (1972-06-01), Hauser
patent: 4515722 (1985-05-01), Yang et al.
patent: 4988682 (1991-01-01), Kozikowski
patent: 5145842 (1992-09-01), Driedger et al.
patent: 5378725 (1995-01-01), Bonjouklian et al.
Yano, Hiroshi, et al., J. Biol. Chem., 268(34):25846-25856 (1993) `Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells`.
Downey, G. P., et al., Am.Rev.Respir.Dis., 143(4PT2):A333 (1991) `Inhibition of actin assembly in neutrophils by 17-hydroxy-wortmannin`.
Kocher, Markus, et al., Febs Letters, 291(2):363-366 (1991) `Effects of 17-hydroxywortmannin on serine/threonine-protein kinases in human blood platelets`.
Plumb, J. A., et al., Proceedings of the American Association For Cancer Research, 34:84 (1993) `Anti-tumor activity of a putative inhibitor of receptor mediated phospholipase D activation`.
Wiesinger, Dorothee, et al., Experientia, 30(2): 135-136 (1974)`Aniinflammatory activity of the new mould metabolite 11-desacetoxy-wortmannin and some of its derivatives`.
Kimura, K., et al., Ninth Annual Meeting on Oncogenes Abstract:203 (1993).
Matter, W. F., et al., Biochem. Biophys. Res. Commun. 186(2):624-631 (1992).
Haeflinger, W., et al., Helv. Chem. Acta, 56(8):2901-2904 (1973).
MacMillan, J., et al., J. Chem. Soc. Perkin I, 2892-2898 (1972).
Abbas, H. K., et al., Appl. Environ. Microbiol., 54(5): 1268-1274 (1988).
Shibasaki, F.., et al., J. Biol. Chem., 266(13):8108-8114 (1991).
Nakanishi, S., et al., J. Biol Chem., 267(4):2157-2163 (1992).
Ohara-Imaizumi, M., et al., Biochem. Biophys. Res. Commun., 185(3):1016-1021 (1992).
Kaplan, D. R., et al., Cell, 50:1027-1029 (1987).
Valius, M., et al., Cell, 73:321-334 (1993).
Coughlin, S. R., et al., Science, 243:1191-1194 (1989).
Baggiolini, M., et al., Exp. Cell Res., 169:408-418 (1987).
John McMurry, Organic Chemistry, pp. 789, 1988.
CA121:32933, Thelen et al, Wortmannin binds . . . , 1994.
CA119:268980, Arcaro et al, Wortmannin is a potent PI-3-Kinase Inhibitor . . . , 1993.
CA119-224160, Yano et al, Inhibition of Histamine Secretion by Wortmannin . . . , 1993.
Bonjouklian Rosanne
Dodge Jeffrey A.
Vlahos Chris J.
Benjamin Roger S.
Boone David E.
Eli Lilly and Company
Fontana Steven A.
Lambkin Deborah
LandOfFree
Inhibition of phosphatidylinositol 3-kinase with 17 .beta.-hydro does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of phosphatidylinositol 3-kinase with 17 .beta.-hydro, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of phosphatidylinositol 3-kinase with 17 .beta.-hydro will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2016553